12-8606849-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_020661.4(AICDA):​c.156+16G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.49 in 1,613,040 control chromosomes in the GnomAD database, including 201,129 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.56 ( 25191 hom., cov: 32)
Exomes 𝑓: 0.48 ( 175938 hom. )

Consequence

AICDA
NM_020661.4 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: 0.291

Publications

17 publications found
Variant links:
Genes affected
AICDA (HGNC:13203): (activation induced cytidine deaminase) This gene encodes a RNA-editing deaminase that is a member of the cytidine deaminase family. AICDA is specifically expressed and active in germinal center-like B cells. In the germinal center, AICDA is involved in somatic hypermutation, gene conversion, and class-switch recombination of immunoglobulin genes. An epigenetic role in neoplastic transformation and lymphoma progression has been experimentally ascribed to AICDA using mouse models. Defects in this gene are the cause of autosomal recessive hyper-IgM immunodeficiency syndrome type 2 (HIGM2). [provided by RefSeq, Jul 2020]
AICDA Gene-Disease associations (from GenCC):
  • hyper-IgM syndrome type 2
    Inheritance: AD, AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 12-8606849-C-T is Benign according to our data. Variant chr12-8606849-C-T is described in ClinVar as Benign. ClinVar VariationId is 261352.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.79 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
AICDANM_020661.4 linkc.156+16G>A intron_variant Intron 2 of 4 ENST00000229335.11 NP_065712.1 Q9GZX7-1Q546Y9Q7Z599
AICDANM_001330343.2 linkc.156+16G>A intron_variant Intron 2 of 4 NP_001317272.1 Q9GZX7-2Q7Z599
AICDANM_001410970.1 linkc.156+16G>A intron_variant Intron 2 of 3 NP_001397899.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
AICDAENST00000229335.11 linkc.156+16G>A intron_variant Intron 2 of 4 1 NM_020661.4 ENSP00000229335.6 Q9GZX7-1

Frequencies

GnomAD3 genomes
AF:
0.559
AC:
84882
AN:
151946
Hom.:
25146
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.740
Gnomad AMI
AF:
0.499
Gnomad AMR
AF:
0.497
Gnomad ASJ
AF:
0.380
Gnomad EAS
AF:
0.810
Gnomad SAS
AF:
0.588
Gnomad FIN
AF:
0.563
Gnomad MID
AF:
0.389
Gnomad NFE
AF:
0.453
Gnomad OTH
AF:
0.494
GnomAD2 exomes
AF:
0.526
AC:
130961
AN:
249030
AF XY:
0.518
show subpopulations
Gnomad AFR exome
AF:
0.744
Gnomad AMR exome
AF:
0.509
Gnomad ASJ exome
AF:
0.375
Gnomad EAS exome
AF:
0.793
Gnomad FIN exome
AF:
0.573
Gnomad NFE exome
AF:
0.455
Gnomad OTH exome
AF:
0.475
GnomAD4 exome
AF:
0.483
AC:
704926
AN:
1460976
Hom.:
175938
Cov.:
43
AF XY:
0.483
AC XY:
351096
AN XY:
726854
show subpopulations
African (AFR)
AF:
0.745
AC:
24944
AN:
33470
American (AMR)
AF:
0.506
AC:
22637
AN:
44698
Ashkenazi Jewish (ASJ)
AF:
0.382
AC:
9981
AN:
26126
East Asian (EAS)
AF:
0.838
AC:
33250
AN:
39690
South Asian (SAS)
AF:
0.564
AC:
48646
AN:
86216
European-Finnish (FIN)
AF:
0.567
AC:
30263
AN:
53338
Middle Eastern (MID)
AF:
0.408
AC:
2354
AN:
5766
European-Non Finnish (NFE)
AF:
0.453
AC:
503129
AN:
1111306
Other (OTH)
AF:
0.492
AC:
29722
AN:
60366
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.465
Heterozygous variant carriers
0
17863
35727
53590
71454
89317
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
15346
30692
46038
61384
76730
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.559
AC:
84987
AN:
152064
Hom.:
25191
Cov.:
32
AF XY:
0.566
AC XY:
42087
AN XY:
74308
show subpopulations
African (AFR)
AF:
0.739
AC:
30680
AN:
41490
American (AMR)
AF:
0.497
AC:
7593
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.380
AC:
1315
AN:
3464
East Asian (EAS)
AF:
0.811
AC:
4199
AN:
5178
South Asian (SAS)
AF:
0.588
AC:
2834
AN:
4820
European-Finnish (FIN)
AF:
0.563
AC:
5946
AN:
10558
Middle Eastern (MID)
AF:
0.405
AC:
119
AN:
294
European-Non Finnish (NFE)
AF:
0.453
AC:
30793
AN:
67960
Other (OTH)
AF:
0.500
AC:
1054
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1820
3640
5461
7281
9101
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
718
1436
2154
2872
3590
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.498
Hom.:
6379
Bravo
AF:
0.559
Asia WGS
AF:
0.681
AC:
2364
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hyper-IgM syndrome type 2 Benign:4
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Oct 09, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:3
Mar 29, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency -

Jan 24, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 66% of patients studied by a panel of primary immunodeficiencies. Number of patients: 63. Only high quality variants are reported. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
0.69
DANN
Benign
0.56
PhyloP100
0.29
PromoterAI
-0.0074
Neutral
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2518144; hg19: chr12-8759445; COSMIC: COSV57565902; API